Get 40% Off
📈 Free Gift Friday: Instantly Copy Legendary Investors' PortfoliosCopy for Free

Prosthetics maker Ottobock draws private equity interest

Published 01/24/2017, 04:15 AM
Updated 01/24/2017, 04:20 AM
© Reuters. A prosthetic foot is seen on a work table in the Ottobock workshop at the Athlete's Village in the Olympic Park in Stratford, east London

By Arno Schuetze

FRANKFURT (Reuters) - Germany's Ottobock, the world's largest maker of artificial limbs, has attracted interest from private equity groups including KKR (N:KKR) and CVC for a 20 percent stake in its core business, people familiar with the matter said on Monday.

The suitors for the stake in its core healthcare division also include buyout firms BC Partners and Advent, the people told Reuters.

The privately held company, owned by the founder's grandson Hans Georg Naeder, said on Friday it was targeting private equity firms, affluent families and technology funds as potential buyers in a deal to be completed by the end of June, ahead of an initial public offering at a later stage.

Ottobock, which started in 1919 as a maker of prosthetics for World War One veterans, said it was currently valued at about 3 billion euros ($3.2 billion) and that it was being advised by J.P. Morgan in the planned stake sale.

Ottobock, an official partner of the International Paralympic Committee, is seeking financial backing to develop more bionic devices; prosthetic limbs and orthotic braces closely modeled on natural mechanisms.

The deal would help it to pursue "even quicker profitable growth and groundbreaking innovations for the people suffering a handicap", Naeder said in the statement.

The valuation would equate to a multiple of 12 times its expected 2017 earnings before interest, tax, depreciation and amortization of 250 million euros, a discount to some rivals as the business includes its lower-margin wheelchair business, one of the people said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Peer Iceland's Ossur (IC:OSSRu) trades at 14.7 times its expected core earnings.

The investment firms and Ottobock declined to comment.

The company said last October it was considering the sale for up to 240 million euros of its Ottobock Kunststoff division, a maker of engineering foams, to focus on healthcare.

Ottobock reported sales of 1.031 billion euros for 2015, of which 847.7 million euros came from its main healthcare unit.

The company said in July 2015 it wanted to go public in 2017, possibly floating a stake of 25 percent with Naeder staying in control. It declined to provide a more specific timeline for the IPO on Monday.

($1 = 0.9310 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.